Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study

The objective of this study was to investigate the efficacy and safety of adjunctive lanicemine (NMDA channel blocker) in the treatment of major depressive disorder (MDD) over 12 weeks. This phase IIb, randomized, parallel-arm, double-blind, placebo-controlled study was conducted at 49 centers in fo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuropsychopharmacology
Autors principals: Sanacora, Gerard, Johnson, Michael R, Khan, Arif, Atkinson, Sarah D, Riesenberg, Robert R, Schronen, Juan P, Burke, Michael A, Zajecka, John M, Barra, Luis, Su, Hong-Lin, Posener, Joel A, Bui, Khanh H, Quirk, Michael C, Piser, Timothy M, Mathew, Sanjay J, Pathak, Sanjeev
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2017
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5312066/
https://ncbi.nlm.nih.gov/pubmed/27681442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/npp.2016.224
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars